Heron Therapeutics filed its 10-Q for the period ended September 30, 2026, reporting 190,273,587 shares of common stock outstanding. The filing highlights a pending Asset Sale to CorMedix and notes significant risks regarding the company's ability to continue as a going concern without additional funding.
Heron Therapeutics reported Q3 2026 net revenue of $35.3 million, a 7.8% decrease year-over-year, driven by a decline in its Oncology franchise despite growth in Acute Care products ZYNRELEF and APONVIE. The company also announced a definitive agreement to sell substantially all of its assets to CorMedix Therapeutics, subject to stockholder approval. Heron ended the quarter with $23.4 million in cash and cash equivalents and did not provide forward financial guidance.
Heron Therapeutics Divestiture to CorMedix Inc. for $145M
Heron Therapeutics has entered into a definitive agreement to sell substantially all of its assets to CorMedix Inc. for $145 million in cash and 14,583,333 shares of CorMedix common stock. The deal includes Heron's commercial portfolio (ZYNRELEF, APONVIE, CINVANTI, and SUSTOL) and provides for up to $55 million in potential earn-out payments plus royalties. Heron will remain a standalone public company, using the proceeds to repay its existing debt and evaluate new strategic investments.
Heron Therapeutics Licensing Deal with Long Grove Pharmaceuticals, LLC
Heron Therapeutics entered into a multi-product Development and License Agreement with Long Grove Pharmaceuticals and Capstone Development Services. The agreement grants Heron an exclusive license to import, distribute, and market certain products in the U.S. in exchange for regulatory milestones, sales-based milestones, and royalty payments.